

Contract Number	Amount Obligated	Total Estimated Contract Value	Center	Awardee Name	Awardee Address	Awardee Zip Code	BAA WP Number	Description of Requirement
75F40121C00088	\$ 224,478.00	\$ 224,478.00	CDER	UNIVERSITY OF MARYLAND103087	3112 LEE BLDG 7809 REGENTS DR COLLEGE PARK	MD 20742-0001	BAA SSBSWP 175	Combating the COVID-19 Infodemic Through Evidence- Based Misinformation Strategies
75F40121C00144	\$ 2,053,902.00	\$ 3,761,678.00	OC	COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION 1595438	CLUNIES ROSS ST BLACK MOUNTAIN ACT 2601 AUSTRALIA	AU 2601	BAA MCMWP 110	Procure a scientific research study entitled: Strengthening COVID-19 animal models and regulatory science using a systems biologyapproach
75F40121C00167	\$ 1,992,223.00	\$ 5,930,261.00	OC	EMBLEEMA INC. 1592090	16 PEARL ST STE 110 METUCHEN NJ	NJ 08840-1847	BAA MCMWP 117	Development and maintenance of FDA-ARGOS 2 containing regulatory grade reference genomes for diagnostic use and regulatory science
75F40121C00185	\$ 926,349.00	\$ 926,349.00	CDER	JOHNS HOPKINS UNIVERSITY 299008	3400 N CHARLES ST BALTIMORE MD	MD 21218-2608	BAA HDDISWP 134	Improving the Efficiency and Rigor of Pharmacovigilance at the Food and Drug Administration
75F40121C00170	\$ 373,488.00	\$ 645,896.00	NCTR	GEORGIA TECH RESEARCH CORPORATION 160612	926 DALNEY ST NW ATLANTA	GA 30332	BAA MCMWP 104	Quantitative, Label-Free Chemical Imaging for Mechanistic Discovery, Identification and Stratification of Disease
75F40121C00154	\$ 378,839.00	\$ 378,839.00	NCTR	UNIVERSITY OF TENNESSEE 103423	62 S DUNLAP STREET STE 103 MEMPHIS	TN 38103-4903	BAA MCMWP 101	Evaluation of Small Animal Models for COVID-19 and their Application in Nonclinical Safety and Efficacy Studies of Investigational Therapeutics
75F40121C00153	\$ 237,550.00	\$ 1,237,710.00	CDER	GEORGIA TECH RESEARCH CORPORATION 160612	926 DALNEY ST NW ATLANTA	GA 30332	BAA PMWP 135	Real time microfluidic cell sensing and sorting to evaluate drug resistance in leukemia cells
75F40121C00194	\$ 2,294,544.00	\$ 14,255,253.00	CBER	ZATA PHARMACEUTICALS INC. 1596760	60 PRESCOTT ST. WORCESTER	MA 016052661	BAA EETWP 58	Universal Closed Systems for Pathogen Reduction in Donated Whole Blood Units
75F40121C00162	\$ 350,353.00	\$ 350,353.00	OC	NORTHWESTERN UNIVERSITY 317125	633 CLARK ST. EVANSTON	IL 60208-0001	BAA HDDISWP 149	Evaluation of a Global Item for Side Effect Bother
75F40121C00092	\$ 3,095,955.00	\$ 3,095,955.00	OC	ST JUDE CHILDRENS RESEARCH HOSPITAL 354326	262 DANNY THOMAS PL MEMPHIS	TN 38105-3678	BAA PMWP 160	Modeling Pediatric Solid Tumors and the Tumor Microenvironment
75F40121C00134	\$ 749,361.96	\$ 749,361.96	OC	CARDINAL HEALTH 127 INC. 1596241	7400 W 110" ST OVERLAND PARK	KS 66210-2358	BAA PMWP 176	Validation of a Novel Methodology for Endpoints Assessing Response to Lymphoma Treatment in Real- World Studies
75F40121C00129	\$ 198,408.00	\$ 198,408.00	OC	MEDICAL COLLEGE OF WISCONSIN 405286	8701 WATERTOWN PLANK RD MILWAUKEE	WI 53226-3548	BAA PMWP 147	Commensurate prior models accommodating historical controls for clinical trials with matched and/or intervalcensored
75F40121C00137	\$ 1,048,942.00	\$ 1,048,942.00	OC	THE CHILDRENS HOSPITAL OF PHILADELPHIA 356961	3401 CIVIC CENTER BLVD PHILADELPHIA	PA 19104-4319	BAA PMWP 143	Pediatric High-Risk Cancer Preclinical Model Resource
75F40121C00143	\$ 100,000.00	\$ 100,000.00	OC	MEDICAL COLLEGE OF WISCONSIN 405286	8701 WATERTOWN PLANK RD MILWAUKEE	WI 53226-3548	BAA PMWP 146	Estimation of Casual Treatment Effects in Hematologic Oncology (HO) Trials in the Presences of Multiple Subsequent Therapies
75F40121C00131	\$ 2,565,626.00	\$ 2,565,626.00	CBER	MASSACHUSETTS INSTITUTE OF TECHNOLOGY 100706	77 MASSACHUSETTS AVE CAMBRIDGE	MA 02139-4301	BAA PMQWP 312	study entitled, "Technologies to enable continuous production of rAAV from Sf9 baculovirus culture"
75F40121C00130	\$ 266,809.00	\$ 480,183.00	CDRH	IDAHO STATE UNIVERSITY 152474	921 S 8" AVE STOP 8219 POCATELLO	ID 83209-0002	BAA EETWP 54	study entitled, "Artificial Intelligence in healthcare understanding patient perspectives and improving patient experiences"
75F40121C00132	\$ 309,976.92	\$ 309,976.92	CDER	THE UNIVERSITY OF AUCKLAND 1432701	24 PRINCES STREET AUCKLAND	NZ 1010	BAA PMQWP 294	study entitled, "Applying a robotic soft esophagus (RoSE) to assess the swallowability of opioid drugs"
75F40121C00133	\$ 1,193,782.00	\$ 1,310,263.00	CDER	UNIVERSITY OF CONNECTICUT 297690	438 WHITNEY RD EXTENSION UNIT 1133 STORRS	CT 06269-1133	BAA PMQWP 304	study entitled, "Enhancement and Validation of In Vitro - In Vivo Correlation Method for Long Acting Injectable Drug Products to Accelerate Their Generic Development"
75F40121C00189	\$ 667,142.00	\$ 667,142.00	CDER	PURDUE UNIVERISTY 311033	155 S GRANT ST WEST LAFAYETTE	IN 47907-2114	BAA PMQWP 329	study entitled "Characterization of Carboxymaltose Variability and Interactions in Ferric Carboxymaltose Complexes"
75F40121C00145	\$ 580,000.00	\$ 580,000.00	CDER	F2G LTD 1595441	F2G LTD LANKRO WAY MANCHESTER	LANCASHIRE M30	BAA PMWP 154	study entitled, "Creation and validation of a patient reported outcome (PRO) instrument for the assessment of health-related quality of life (HRQOL) in patients with coccidioidomycosis"
75F40121C00128	\$ 249,975.00	\$ 249,975.00	CDER	HARTFORD HOSPITAL 1364439	80 SEYMOUR ST HARTFORD	CT 06102-8000	BAA PMWP 156	study entitled, "A critical look at cefepime breakpoints in vivo an assessment of cefepime activity against carbapenemase-producing Enterobacterales with unexpected cefepime"
75F40121C00127	\$ 307,205.00	\$ 307,205.00	CDER	JOHNS HOPKINS UNIVERSITY 299008	3400 N CHARLES ST BALTIMORE	MD 21218-2698	BAA PMWP 173	study entitled, "To Provide Evaluating the Impact of Extended-Infusion ?-lactam Administration Strategies on Improving Clinical Outcomes and Reducing the Subsequent Emergence of Antimicrobial Resistance"
75F40121C00126	\$ 388,347.00	\$ 388,347.00	CDER	THE UNIVERSITY OF QUEENSLAND 1249762	LEVEL 8, UQ CENTER FOR CLINICAL RESEARCH ROYAL BRISBANE AND WOMENS HOSPITAL	AU QLD 4029	BAA PMWP 170	study entitled, "Continuous vs intermittent infusion of beta-lactam antibacterial drugs impact on resistance and outcomes in sepsis"
75F40121C00158	\$ 299,924.00	\$ 299,924.00	CBER	DUKE UNIVERSITY 132317	2200 W MAIN ST STE 710 DURHAM	NC 27708-4677	BAA PMWP 172	Using simulation modeling and real-world data to monitor the effectiveness of the COVID-19 vaccine
75F40121C00148	\$ 316,471.00	\$ 1,487,081.00	CDER	REGENTS OF THE UNIVERSITY OF MICHIGAN 221536	503 THOMPSON ST ANN ARBOR	MI 48109-1340	BAA SSBSWP 189	study entitled, "A Mosaic Approach for Understanding Stimulant Use, Misuse and Use Disorder Trajectories"
75F40121C00149	\$ 683,353.00	\$ 1,156,751.00	CDER	UNIVERSITY OF CALIFORNIA 158384	1855 FOLSOM ST STE 425 SAN FRANCISCO	CA 94143-4249	BAA SSBSWP 179	conduct a study entitled, "A Multidisciplinary Approach to Understanding Stimulant Use Disorders: Use Trajectories, Medical Consequences and Treatment Goals"
75F40121C00109	\$ 2,814,105.00	\$ 2,814,105.00	CBER	REGENTS OF THE UNIVERISTY OF CALIFORNIA 228475	10889 WILSHIRE BLVD STE 700 LOS ANGELES	CA 90024-4201	BAA GLOBWP 60	study entitled, "Strengthening Pharmacovigilance Systems and Adverse Events Reporting for Maternal Immunization Safety in the Democratic Republic of Congo"
75F40121C00157	\$ 499,445.00	\$ 499,445.00	CDER	UNIVERSITY OF FLORIDA 147908	1523 UNION RD RM 207 GAINSVILLE	FL 32611-1941	BAA PMWP 148	conduct a study entitled, "Beta-lactam continuous versus intermittent infusion and associated bacterial resistance and therapy outcomes in critically ill patients with severe pneumonia"

75F40121C00184	\$ 249,999.00	\$ 249,999.00	CDER	HARTFORD HOSPITAL 1364439	80 SEYMOUR ST HARTFORD	CT 06102-8000	BAA PMWP 166	study entitled, "Ampicillin-Sulbactam against Acinetobacter baumannii infections: Pharmacokinetic/Pharmacodynamic Appraisal of Current Susceptibility Breakpoints and Dosing Recommendations"
75F40121C00136	\$ 794,004.00	\$ 794,004.00	CDER	PURDUE UNIVERISTY 311033	155 S GRANT ST WEST LAFAYETTE	IN 47907-2114	BAA PMQWP 298	study entitled, "Assessment tools for surveillance and monitoring fo real-world data systems and processes to ensure product quality"
75F40121C00096	\$ 63,081.00	\$ 63,081.00	OC	HAPATITIS B FOUNDATION 1592041	3805 OLD EASTON TD DOYLESTOWN	PA 18902-8400	BAA HDDISWP 132	study entitled "Improving clinical trial diversity and participation among people living with chronic hepatitis B Perceptions and challenges"
75F40121C00111	\$ 3,572,685.00	\$ 4,999,325.00	CDER	MASSACHUSETTS UNSTITUTE OF TECHNOLOGY 100706	77 MASSACHUSETTS AVE CAMBRIDGE	MA 02139-4301	BAA PMQWP 324	Controlled Protein Capture via Continuous Crystallization and Precipitation for Monoclonal Antibody Manufacturing
75F40121C00138	\$ 700,000.00	\$ 700,000.00	CDER	ACADEMISCH ZIEKENHUIS LEIDEN 1139836	ALBINUSDREEF 2 LEIDEN ZUID- HOLLAND	LEIDEN ZUID HOLLAND 2333	BAA PMWP 142	Study entitled, "Reversal of Opioid-induced respiratory depression with opioid antagonists A Study in opioid individuals and chronic opioid users under real-life conditions"
75F40121C00106	\$ 2,279,621.00	\$ 4,198,914.00	CDER	RUTGERS, THE STATE UNIVERSITY 299012	3 RUTGETS PLAZA NEW BRUNSWICK	NJ 08901-8559	BAA PMQWP 309	Study entitled, "Integrated toolbox for digital design, scale- up, control, and optimization of advanced API manufacturing processes"
75F40121C00119	\$ 600,000.00	\$ 1,200,000.00	CDER	THE UNIVERSITY OF MISSISSIPPI 354320	113 FALKNER	MS 38677-9704	BAA PMQWP 338	Study entitled, "Preventable Harm from Pediatric Outpatient Medication Errors:
75F40121C00161	\$ 391,759.25	\$ 391,759.25	CDER	UNIVERSITAT ST.GALLEN 1592134	DUFOURSTRASSE 50 ST. GALLEN	ST. GALLEN SG 9000	BAA PMQWP 336	Conduct a study entitled, "RiskSurve - Towards a Holistic Risk-based Site Surveillance An approach for remote, data- based site risk identification and inspection preparation in a (Post-) COVID-19Environment"
75F40121C00090	\$ 5,000,001.00	\$ 5,000,001.00	CDER	MASSACHUSETTS INSTITUTE OF TECHNOLOGY 100706	77 MASSACHUSETTS AVE CAMBRIDGE	MA 021394301	BAA PMQWP 314	study entitled, "Application of Smart Data Analytics for Biomanufacturin"
75F40121C00150	\$ 1,399,298.00	\$ 1,399,298.00	CDER	UNIVERSITY OF CONNECTICUT 297690	438 WHITNEY RD EXTENSION UNIT 1133 STORRS	CT 06269-1133	BAA EETWP 56	Study entitled, "Comparative Trial of Different Packaging Components of an Opioid Packaging Solution on Opioid Safety Outcomes"
75F40121C00177	\$ 500,000.00	\$ 500,000.00	OC	HOWARD UNIVERSITY 347586	2400 6 <sup>th</sup> ST NW WASHINGTON	DC 20059-0001	BAA MCMWP 111	study entitled, "Bridging Gaps: Recruiting African and Asian American Participants in Clinical Trials and Creating Culturally Competent Messages"
75F40121C00188	\$ 749,980.00	\$ 749,980.00	CDER	UNIVERSITY OF FLORIDA 147908	1523 UNION RD RM 207 GAINSVILLE	FL 32611-1941	BAA SSBSWP 173	Study entitled, "Teratogenic Risk Impact and Mitigation (TRIM): An Evidence-based Decision Framework"
75F40121C00020	\$ 272,553.00	\$ 386,781.00	CDER	JOHANNES GUTENBER- UNIVERSITAT MAINZ 1585755	JOHANNES GUTENBER- UNIVERSITAT MAIN SAARSTR. 21	MAINZ RHEINLAND- PFLAZ 55122	BAA PMQWP 259	Study entitled, "Disintegration and dissolution of solid dosage forms and influence of food induced viscosity on its kinetics, tools and methodologies for bioequivalence and substitutability evaluation"
75F40121C00087	\$ 2,696,737.00	\$ 5,504,916.00	OC	AETION INC 1591094	5 PENN PLZ FL 7 NEW YORK	NY 100011837	BAA MCMWP 97	study entitled, "Real-world evidence for rapid, systematic assessment of COVID-19 countermeasures? safety and effectiveness in inpatient settings"
75F40121C00082	\$ 393,043.00	\$ 393,043.00	OC	MEDSTAR RESEARCH INSTITUTE 283696	6525 BELCREST RD STE 700 HYATTSVILLE	MD 207822031	BAA SSBSWP 184	study entitled: "Artificial Intelligence (AI) Supported Annotation of FAERS Reports"
75F40121C00120	\$ 599,723.00	\$ 599,723.00	CDER	OREGON HEALTH & SCIENCE UNIVERSITY 160276	3181 SW SAM JACKSON PARK RD PORTLAND	OR 97239-3011	PMWP 183	Study entitled, "Development of pulmonary nontuberculous mycobacterial disease symptom scale (NTM-SS) pulmonary NTM infection"
75F40121C00022	\$ 683,910.00	\$683,910.00	CDER	AUBURN UNIVERSITY 280440	107 SAMFORD HALL AUBURN	AL 36849-0001	SSBSWP 165	Study entitled, "Assessment of a pharmacist-led transitions of care service utilizing an admission-enhanced patient risk evaluation approach"
<b>Totals</b>	<b>\$46,112,948.13</b>	<b>\$73,834,242.13</b>						